Don Dizon, MD, on Creating a Gender-Affirming Environment for Transgender Patients With Cancer


Don Dizon, MD, FACP, FASCO, describes the importance of establishing a gender-affirming environment for patients with cancer.

In an interview with CancerNetwork®, Don Dizon, MD, FACP, FASCO, director of women’s cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and professor of medicine at the Warren Alpert Medical School of Brown University in Providence, explained how providers can create a more welcoming environment for transgender patients with cancer. He said that mission statements supporting this patient population and physical infrastructure choices such as gender-neutral bathrooms and magazine choices can be helpful in making transgender men, lesbian women, and cisgender men feel comfortable in breast cancer clinics.


Several things can be done to physical infrastructure, and certainly to mission statements. Those are easier to do than others. Having a mission statement that espouses a quality that really reaffirms sexual orientation as a human right, that affirms gender as a human right that is to be respected and not maligned [is important]. Then looking at your waiting areas, seeing that there are bathrooms for men, for women, and one that's not labeled [is also worth considering]. Having diversity of your magazines in your waiting area [can also create a welcoming environment]. It shouldn't all be Cosmopolitan and Time magazine. Some of them should be gender neutral [and not] speak to men or women. You [need to] think of the physical infrastructure—the feng shui of your place—and you want to see that anyone who walks into this area is welcome. This is the biggest issue regarding women's cancer centers. The Center for Women's Oncology or the Center for Breast Cancer Care, all adorned in pink, all adorned with female imagery, all adorned with female breasts, is not necessarily going to be that welcoming to the transgender male who has breast cancer, or the lesbian who has breast cancer, and all she sees are heterosexual partners. But it's also not going to be welcoming to men with breast cancer either.

Related Videos
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Lucio N. Gordan, MD, also discusses how increasing domestic manufacturing of chemotherapy may help in alleviating the ongoing shortages of carboplatin and cisplatin in the United States.
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, believes that national legislation can help to resolve the United States’ current dearth of cisplatin, as well as prevent future problems.
Using an AUC of 5 instead of an AUC of 6 can help to conserve cisplatin among patients with cancer, Kirollos Hanna, PharmD, BCPS, BCOP, FACCC says.
While there is a cisplatin shortage in the United States, the FDA has approved the importation of select chemotherapy drugs from China to help mitigate the scarcity of the agents.
Recommendations penned by the American Society of Clinical Oncology and Society for Gynecologic Oncology may be critical in managing the ongoing chemotherapy shortage, according to Michael Ganio, PharmD, MS, BCPS, FASHP.
Related Content